New diagnostic isotope to enhance targeted alpha therapy for cancer

Los Alamos scientist Veronika Mocko processing cerium-134 in the "Hot Cells" at Los Alamos National Laboratory.

Los Alamos scientist Veronika Mocko processing cerium-134 in the "Hot Cells" at Los Alamos National Laboratory.

Researchers in the DOE Isotope Program have developed an effective radionuclide, cerium-134, as a paired analogue of actinium and thorium that can be imaged using positron emission tomography (PET). Establishing a routine production pathway for cerium-134 is an essential step in advancing the use of the alpha emitters for cancer therapy.

“This advancement offers new possibilities for medical staff and drug developers to better characterize new actinium and thorium therapeutics,” said Stosh Kozimor, lead Los Alamos National Laboratory researcher on the joint project with Lawrence Berkeley National Laboratory, the University of California, and the University of Wisconsin.

See full highlight at LANL.GOV